Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05575076 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension for Phase 3 Clinical Trials of Simufilam
A Phase 3 study, sponsored by Cassava Sciences.
- Terminated
- Registry status
- Phase 3
- Development phase
- 1,081
- Enrollment target
NCT05575076 is a Phase 3 study that was terminated before completion, run by Cassava Sciences. The registered enrollment target is 1,081 participants.
The verdict
NCT05575076, a Phase 3 study, was terminated before completion, sponsored by Cassava Sciences.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 1,081 participants
- Enrollment target
Study Summary
The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
Interventions
- DRUG Simufilam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,081 participants |
| Start Date | 2022-11-07 |
| Est. Completion | 2025-01-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05575076
The ClinicalTrials.gov registry entry for NCT05575076 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 1,081 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cassava Sciences, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Simufilam is the first listed.
NCT05575076 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05575076 about?
NCT05575076 is a clinical study titled "Open-label Extension for Phase 3 Clinical Trials of Simufilam". The goal of this open-label extension study is to assess long-term safety and tolerability of simufilam 100 mg in subjects who have completed the RETHINK-ALZ or REFOCUS-ALZ Phase 3 clinical trials.
What is the current status of trial NCT05575076?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 1,081 participants. The study started on 2022-11-07. Estimated completion is 2025-01-31.
What interventions are being tested in trial NCT05575076?
The interventions under investigation include: Simufilam (DRUG).
Who is sponsoring clinical trial NCT05575076?
This trial is sponsored by Cassava Sciences, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.